Mesoblast (MESO) Sees Optimism From Analysts

We recently published 7 Best ASX Stocks to Buy Right Now. Mesoblast Limited (NASDAQ:MESO) is one of the best ASX stocks.

Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases, heart failure, and other ailments. On November 25th, Jefferies upgraded the firm’s shares to Buy from Hold and increased the share price target to AUD3.30 from AUD3.00. The financial firm cited Mesoblast Limited (NASDAQ:MESO)’s Ryoncil drug as the reason behind its optimism. Jefferies explained that Ryoncil brought in $30 million in gross revenue in Mesoblast Limited (NASDAQ:MESO)’s fiscal second quarter to meet Jefferies’ estimates. Jefferies also estimated that 14 patients completed treatment with the medicine during the second quarter, and added that a total of 78 patients could complete treatment in 2026.

Mesoblast Limited (NASDAQ:MESO) has been scoring major wins with Ryoncil in 2026. For instance, the firm announced on October 3rd that its drug had secured a J-Code by the Medicare and Medicaid services. The classification was an important win for Mesoblast Limited (NASDAQ:MESO) since it allowed the drug to benefit from Medicare and Medicaid reimbursements and expanded its availability across the US. Additionally, Ryoncil was the first drug of its kind to receive this designation. The drug is designed to be used in pediatric patients whose cells are being attacked by donor cells after a stem cell transplant.